ISIN:CH0038389992

DGAP-News: BB BIOTECH AG: Successful vaccination campaigns point the way out of the corona crisis - sector re-valuation used for portfolio investments

Venerdì, Aprile 23, 2021 - 10:49pm

Its stock ended the quarter with a positive total return of 15.4% in CHF and 14.3% in EUR.

Key Points: 
  • Its stock ended the quarter with a positive total return of 15.4% in CHF and 14.3% in EUR.
  • Countries such as Israel, the US and the UK that secured early access to vaccines have experienced sharp drops in infection and hospitalization rates.
  • Although most other countries are making slower progress with their vaccination campaigns, they are likely to eventually show similar developments.
  • This should have a variety of positive effects on companies in the biotech sector.

DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals and approve the dividend of CHF 3.60 per share

Giovedì, Marzo 18, 2021 - 5:01pm

BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy.

Key Points: 
  • BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy.
  • Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe.
  • BB Biotech is one of the leading investors in this sector.
  • As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard.

DGAP-News: BB Biotech AG publishes its 2020 annual report

Venerdì, Febbraio 19, 2021 - 7:00am

Media release as of February 19, 2021

Key Points: 
  • Media release as of February 19, 2021
    Annual report of BB Biotech AG as of December 31, 2020
    BB Biotech AG published its annual report for fiscal year 2020 today.
  • Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech's positioning, the investment areas covered by its portfolio and the companies it is invested in.
  • As already announced on January 22, 2021, BB Biotech will propose a dividend of CHF 3.60 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2020.
  • BB Biotech's annual report 2020 is available under report.bbbiotech.ch/2020/en resp.